

Severe Adverse Effects

- hyperkalemia / Delayed / 0-45.0
- heart failure / Delayed / 3.1-14.9
- pleural effusion / Delayed / 22.0-36.0
- GI perforation / Delayed / 3.1-14.9
- oliguria / Early / 0-19.0
- GI bleeding / Delayed / 3.1-14.9
- renal failure (unspecified) / Delayed / 0-15.0
- esophageal ulceration / Delayed / 3.1-14.9
- ileus / Delayed / 3.1-14.9
- bradycardia / Rapid / 3.1-14.9
- coagulopathy / Delayed / 3.1-14.9
- seizures / Delayed / 0-15.0
- exfoliative dermatitis / Delayed / 0-14.9
- stroke / Early / 3.1-14.9
- pneumothorax / Early / 3.1-14.9
- thrombosis / Delayed / 3.1-14.9
- atrial fibrillation / Early / 0-15.0
- angioedema / Rapid / 1.0-2.0
- pericardial effusion / Delayed / 15.0-15.0
- cardiomyopathy / Delayed / 0-1.0
- anaphylactoid reactions / Rapid / 0-1.0
- pulmonary edema / Early / 0-15.0
- hemolytic anemia / Delayed / 0-15.0
- cardiac valvulopathy / Delayed / 0.2-0.9
- anasarca / Delayed / 0-15.0
- nephrotoxicity / Delayed / 10.0^[1]

[1] - Prograf (tacrolimus) dose, indications, adverse effects, interactions... from PDR.net
<https://www.pdr.net/drug-summary/Prograf-tacrolimus-1331#12>, accessed: 2021-11-29

